Supernus pharmaceuticals, inc. (SUPN)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11
Assets
Current assets
Cash and cash equivalents

225,767

181,381

116,889

87,344

122,778

192,248

123,818

35,205

444,140

100,304

81,924

61,737

59,599

66,398

54,305

36,156

19,830

33,498

25,641

32,457

25,158

36,396

37,780

11,956

12,252

32,980

22,945

33,907

18,909

40,302

23,412

47,242

15,866

48,544

Marketable securities

175,104

165,692

179,808

171,222

170,165

163,770

156,407

139,208

45,585

39,736

32,626

31,229

27,533

23,723

26,024

24,058

25,427

28,692

32,061

37,334

39,678

37,940

34,783

35,314

46,615

49,211

64,293

68,725

50,983

48,206

37,256

29,150

21,513

-

Marketable securities - restricted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

275

259

276

245

Accounts receivable, net

119,195

87,332

86,699

84,564

79,950

102,922

77,753

74,842

67,864

65,586

56,166

51,157

38,885

41,527

36,220

34,281

30,651

25,908

23,603

17,900

19,271

17,270

15,303

10,854

9,725

5,054

7,208

537

1,650

11

500

-

-

-

Interest receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

496

636

-

982

791

672

664

-

-

-

-

Inventories, net

24,418

26,628

25,504

26,024

26,518

25,659

23,280

20,680

19,075

16,304

14,947

16,623

19,167

16,801

17,453

16,373

13,044

12,587

14,742

13,592

13,702

13,441

11,145

10,101

7,957

7,152

5,188

4,315

3,113

1,152

26

-

-

-

Prepaid expenses and other current assets

12,564

11,611

18,182

21,757

20,556

8,888

9,299

14,581

6,582

6,521

5,667

4,746

4,573

2,955

4,201

3,272

5,003

5,261

6,468

4,417

3,640

3,679

3,791

3,058

2,559

2,764

1,815

1,912

861

983

1,276

1,010

618

466

Deferred financing costs, current

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

202

185

-

431

430

144

144

144

144

144

144

Total current assets

557,048

472,644

427,082

390,911

419,967

493,487

390,557

284,516

583,246

228,451

191,330

165,492

149,757

151,404

138,203

114,140

93,955

105,946

102,515

105,700

101,449

108,726

102,802

71,981

79,929

97,161

102,862

110,617

76,332

91,462

62,889

77,805

38,417

49,399

Long term marketable securities

534,712

591,773

596,442

593,754

522,551

418,798

460,304

503,312

175,064

133,638

123,123

104,632

89,163

75,410

67,044

67,809

68,790

55,009

43,967

33,488

27,315

19,816

15,763

15,462

11,662

8,756

15,215

16,072

-

-

1,804

-

-

-

Property and equipment, net

18,011

17,068

9,977

4,028

4,226

4,095

6,930

4,897

5,003

5,124

4,688

4,572

4,342

4,344

4,318

4,193

3,866

3,874

3,210

2,908

2,481

2,448

2,500

2,590

2,648

2,554

2,480

2,247

1,687

1,421

1,384

1,146

1,183

1,310

Deferred legal fees

-

-

-

-

-

-

-

-

-

-

-

11,887

11,331

-

17,437

16,386

11,444

22,503

-

11,487

7,672

-

-

-

-

-

-

-

-

-

-

-

-

-

Intangible assets, net

23,579

24,840

26,101

28,787

30,063

31,368

32,572

33,794

34,858

36,019

37,162

28,989

29,450

36,350

15,526

15,785

16,108

976

16,627

110

167

5,434

4,135

3,083

2,157

1,158

817

568

626

683

740

798

855

912

Lease assets

21,911

21,279

18,780

19,639

20,049

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income taxes

34,067

32,063

27,953

25,975

27,967

29,683

31,367

25,528

26,254

20,843

28,807

30,449

37,863

41,729

42,256

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

538

615

574

581

625

380

782

752

735

389

368

349

350

331

332

320

311

318

322

321

321

360

360

361

360

1,366

360

360

363

334

55

55

61

55

Deferred financing costs, long-term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

713

764

-

2,031

2,109

53

89

142

161

2,686

2,054

Total assets

1,189,866

1,160,282

1,106,909

1,063,675

1,025,448

977,811

922,512

852,799

825,160

424,464

385,478

346,370

322,256

309,568

285,116

218,633

194,474

188,626

166,641

154,014

139,405

136,784

125,560

94,190

97,520

110,995

123,765

131,973

79,061

93,989

67,014

79,965

43,202

53,730

Liabilities and stockholders’ equity
Current liabilities
Accounts payable

3,124

10,141

3,090

4,081

7,240

3,195

9,838

2,943

3,333

6,844

6,262

7,577

5,056

8,055

2,685

2,243

2,646

4,314

2,812

4,518

859

1,863

1,573

-

-

3,142

-

-

-

-

-

-

-

-

Accrued product returns and rebates

119,453

107,629

98,050

95,934

88,200

107,063

85,970

70,044

73,034

68,343

59,772

47,621

43,450

41,943

39,694

35,019

28,697

26,794

18,820

14,114

10,025

8,461

7,298

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

33,003

37,130

40,800

38,614

36,607

36,535

32,098

29,288

25,024

27,305

26,892

23,434

26,890

27,427

26,719

28,135

22,915

25,153

21,654

17,856

16,482

17,656

13,112

-

-

15,172

-

-

-

-

-

-

-

-

Income taxes payable

9,097

2,443

4,818

2,674

17,233

12,377

8,548

-

16,265

15,938

6,489

1,608

1,675

7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Nonrecourse liability related to sale of future royalties, current portion

3,658

3,244

2,959

2,668

2,426

2,183

1,892

1,659

1,432

4,283

5,254

4,997

4,645

3,101

2,342

1,909

1,067

497

261

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred licensing revenue

-

-

-

-

-

-

-

-

-

287

287

287

287

209

207

208

208

176

143

143

143

143

143

143

173

204

234

325

417

508

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

19,044

14,658

-

14,472

11,732

10,903

10,666

10,485

9,175

9,337

11,763

Deferred product revenue, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,271

7,882

10,365

3,967

3,551

-

-

-

-

-

Interest payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

238

259

271

-

Secured notes payable, net of discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,137

11,809

11,490

10,747

9,171

6,775

Total current liabilities

168,335

160,587

149,717

143,971

151,706

161,353

138,346

103,934

119,088

123,000

104,956

85,524

82,003

80,742

71,647

67,514

55,533

56,934

43,690

36,631

27,509

28,123

22,126

19,187

27,102

26,400

25,071

16,024

27,008

22,983

24,590

21,881

19,912

18,770

Deferred licensing revenue, net of current portion

-

-

-

-

-

-

-

-

-

1,149

1,221

1,293

1,365

1,501

1,554

1,606

1,658

1,390

1,167

1,202

1,238

1,274

1,310

1,345

1,381

1,417

1,452

738

774

309

576

365

232

232

Accrued compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,801

1,335

901

-

Convertible notes, net

349,232

345,170

341,163

337,210

333,310

329,462

325,666

321,920

318,225

-

-

1,472

3,310

4,165

5,772

5,699

5,627

7,085

7,939

8,608

11,476

26,223

25,732

28,671

28,358

34,393

60,175

59,100

-

-

-

-

-

-

Deferred revenue, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

381

183

407

465

Nonrecourse liability related to sale of future royalties, long term

18,369

19,248

20,305

21,100

21,957

22,575

23,305

23,867

24,370

22,258

22,702

24,184

25,555

27,289

28,286

28,855

29,621

30,031

30,287

30,326

30,179

30,025

30,127

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities, long term

30,804

30,440

27,256

27,535

27,824

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Secured notes payable, net of current portion and discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,975

11,088

14,116

17,061

19,926

22,711

Other liabilities

9,743

9,409

11,211

10,955

10,633

11,398

13,259

12,586

11,608

10,577

4,936

4,500

3,936

4,002

4,199

4,322

4,391

4,325

3,815

3,355

2,561

3,876

3,015

2,784

2,101

2,677

2,401

2,158

1,860

1,788

1,558

1,432

1,382

1,399

Supplemental executive retirement plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

275

259

276

245

Derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

23

114

287

412

535

854

1,156

2,070

2,691

6,564

7,258

8,834

9,565

12,644

22,213

18,061

172

251

1,463

1,169

1,025

697

Total liabilities

576,483

564,854

549,652

540,771

545,430

524,788

500,576

462,307

473,291

156,984

133,815

116,973

116,192

117,813

111,745

108,408

97,365

100,619

88,054

82,192

75,654

96,085

89,568

60,821

68,507

77,531

111,312

96,081

37,789

36,419

42,383

41,985

42,928

44,287

Stockholders’ equity
Series A preferred stock, $0.001par value - 65,000,000 shares authorized at March 31, 2013 and December 31, 2012; zero shares issued and outstanding at March 31, 2013 and December 31, 2012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

49

49

Common stock, $0.001 par value; 130,000,000 shares authorized; 52,537,159 and 52,533,348 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

53

53

52

52

52

52

52

52

52

51

51

51

50

50

50

50

49

49

49

48

48

43

43

42

42

40

31

31

31

31

24

24

2

2

Additional paid-in capital

392,430

388,410

383,525

379,369

373,707

369,637

365,396

361,971

352,257

294,999

291,841

285,572

279,792

276,127

271,801

270,059

267,576

263,955

261,006

258,202

252,483

230,263

229,225

224,196

223,041

211,952

168,625

168,122

145,999

143,851

97,378

97,209

49,462

49,362

Accumulated other comprehensive earnings (loss), net of tax

-166

7,417

7,261

5,924

1,427

-3,158

-4,111

-4,119

-2,291

-747

252

216

32

-134

127

549

168

-488

-107

-151

-65

-154

-35

1

1

-

-81

-235

-89

-57

-29

6

8

1

Retained earnings

221,066

199,548

166,419

137,559

104,832

86,492

60,599

32,588

1,851

-26,823

-40,481

-56,442

-73,810

-84,288

-98,607

-160,433

-170,684

-175,509

-182,361

-186,277

-188,715

-189,453

-193,241

-190,870

-194,071

-178,528

-156,122

-132,026

-104,669

-86,255

-72,742

-59,259

-49,247

-39,971

Total stockholders’ equity

613,383

595,428

557,257

522,904

480,018

453,023

421,936

390,492

351,869

267,480

251,663

229,397

206,064

191,755

173,371

110,225

97,109

88,007

78,587

71,822

63,751

40,699

35,992

33,369

29,013

33,464

12,453

35,892

41,272

57,570

24,631

37,980

274

9,443

Total liabilities and stockholders’ equity

1,189,866

1,160,282

1,106,909

1,063,675

1,025,448

977,811

922,512

852,799

825,160

424,464

385,478

346,370

322,256

309,568

285,116

218,633

194,474

188,626

166,641

154,014

139,405

136,784

125,560

94,190

97,520

110,995

123,765

131,973

79,061

93,989

67,014

79,965

43,202

53,730